[Federal Register Volume 72, Number 153 (Thursday, August 9, 2007)]
[Notices]
[Pages 44859-44860]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-15553]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952(a)(2) authorizing the importation of 
such substances, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on May 17, 2007, Aptuit (Allendale), Inc., 75 Commerce Drive, 
Allendale, New Jersey 07401, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as an importer of 
Noroxymorphone (9668), a basic class of controlled substance listed in 
schedule II.
    The company plans to import the basic class of controlled substance 
for clinical trials and research.
    Any manufacturer who presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC 20537; or any being sent via express mail should be sent 
to, Drug

[[Page 44860]]

Enforcement Administration, Office of Diversion Control, Federal 
Register Representative (ODL), 2401 Jefferson-Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than September 
10, 2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substances in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), 
(c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-15553 Filed 8-8-07; 8:45 am]
BILLING CODE 4410-09-P